Biopsy Devices Market: Key Players Analysis Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts

The Biopsy Devices market is anticipated to grow at US$ 4.02 billion by 2033 from US$ 2.43 billion in 2024 at a CAGR of 5.75% during the period of 2025 to 2033. A few of the primary drivers of the market include the increasing need for personalized care, the increasing prevalence of cancer, and the need for minimally invasive treatments to enhance patient comfort and reduce recovery times.

Biopsy equipment are medical devices used to remove tissue samples from the body for the purposes of diagnosis. Biopsy equipment is very important in disease identification, especially cancer, since it enables doctors to examine cells in a laboratory environment. There are different types of biopsy equipment such as needle biopsy equipment, punch biopsy equipment, and surgical biopsy tools, each specific to a different medical condition or body area.

Needle biopsy machines, including fine-needle aspirators and core needle biopsy systems, can be utilized for non-invasive sampling, enabling physicians to obtain tissue with minimal effect on healthy tissue in the area. Punch biopsy equipment is frequently used for skin sampling, whereas surgical biopsy equipment can be required for deeper or more extensive tissue sampling.

Use of biopsy devices makes early diagnosis and correct detection possible, allowing for timely and suitable treatment strategies. Biopsy devices are becoming more accurate and less invasive as technology evolves, making them more comfortable for patients and enhancing the quality of care. Their role in contemporary medicine cannot be overemphasized since they offer critical information for guiding treatment and improving patient care.

Leading Biopsy Device Companies & Profiles

Cardinal Health, Inc.

Year of establishment: 1971
Head office: United States

Biopsy devices are medical devices employed for removing tissue samples to aid in diagnosis, mainly for the detection of diseases such as cancer. Some varieties include needle biopsy devices, punch biopsy instruments, and surgical devices, each designed specifically for certain conditions and body areas. Non-invasive sampling with little damage to healthy tissue can be achieved using needle biopsies, such as fine-needle aspirators. Punch biopsy equipment is applied for skin, whereas surgical instruments are required for deeper or bigger tissues. The equipment plays a vital role in early detection and correct diagnosis, allowing timely treatment. New technologies are further refining these devices as more precise and less invasive, thus ending up enhancing patient comfort and outcomes. Their function in contemporary medicine is critical to decision-making treatment and reinforcing patient care.

Hologic Inc.

Foundation: 1985
Headquarters: United States

Hologic Inc (Hologic) designs, produces, and distributes medical imaging solutions, diagnostic products, and surgical systems. It provides products that assist in the diagnosis of human ailments; breast imaging products and related products and accessories; GYN surgical instruments, such as endometrial ablation systems and hysteroscopic tissue removal systems; and skeletal health solutions like dual-energy X-ray bone density measurement systems and mini C-arm imaging systems. The company sells its products to surgeons, hospitals, clinical laboratories, and physicians. Hologic distributes its products and services using both direct sales and an independent network of sales agents and distributors. The company is active in Europe, the Americas, and the Asia-Pacific region.

Danaher Corporation

Founded: 1984
Headquarters: United States

Danaher Corp (Danaher) is a technology and science company dealing in biotechnology, diagnostics, and life sciences. The company deals in a variety of test devices, diagnostic medical instruments, life science research equipment, professional microscopes, reagents and mass spectrometry, genomic supplies, filtration and flow cytometry, genomics, laboratory automation, centrifugation, particle counting, and characterization products. Danaher sells its products to pharmaceutical and biotechnology firms, healthcare practitioners, and research institutions through independent distributors in the Americas, Europe, Middle East, Africa, and Asia-Pacific. Danaher has manufacturing bases in Europe, Australia, Asia, and the Americas.

Becton, Dickinson and Company

Establishment: 1897
Headquarter: United States

Becton Dickinson and Co (BD) is a medical technology company. It produces and distributes medical devices, medical consumables, laboratory products, and diagnostic instruments. Products offered by the company range from vascular and urology instruments to surgical products, molecular diagnostics systems, infusion pumps, pre-fillable drug delivery systems, hemodynamic monitoring systems, and cell analysis solutions. BD markets its offerings to healthcare facilities, physicians, life science researchers, clinical research laboratories, the pharmaceutical industry, and consumers. BD has facilities in several nations, including manufacturing facilities in Bosnia and Herzegovina, Brazil, Canada, the United States of America, the Dominican Republic, France, Germany, Hungary, India, Japan, and Mexico, among other countries.

Boston Scientific Corporation

Founding: 1979
Headquarter: United States

Boston Scientific Corp (Boston Scientific) is a medical technology company that develops, produces, and markets products for various interventional medical applications. The company has products in the fields of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery. Boston Scientific distributes its products to hospitals, clinics, outpatient centers, and medical offices worldwide. The company has manufacturing facilities in the United States, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It markets its products directly as well as indirectly by way of a distribution network and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas.

Medtronic plc. Biopsy Devices Product Launches

In April of 2024, Medtronic unveiled its ColonPRO software, a major innovation for the GI Genius™ intelligent endoscopy solution. This revolutionary software is a key part of an AI-powered platform engineered to improve the detection and identification of colorectal polyps. With its enhanced capabilities, ColonPRO is designed to enhance diagnostic accuracy and simplify the process of the endoscopic examination, ultimately leading to improved patient outcomes in colorectal health.

Olympus Corporation Biopsy Devices Product Launches

October 2025 - Olympus Corporation, a worldwide MedTech company, launched SecureFlex, a single-use fine needle biopsy tool. Ready for commercial release in Europe and Japan this Autumn, with subsequent roll-out worldwide, SecureFlex is intended for use with ultrasound endoscopy and facilitates endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) of gastrointestinal tract lesions, with the primary use being for the diagnosis of pancreatic cancer.

SWOT Analysis of the Cook Medical Company

Strength: Cook Medical's Precision Innovation in Biopsy Devices - Cook Medical leads the biopsy devices market by remaining innovative continuously, especially with items such as the EchoTip ClearCore EUS Biopsy Needle, with a cobalt-chromium Franseen tip and spring-coiled sheath to provide greater flexibility and accuracy. The technology enables sharper puncture force and better quality tissue sampling, essential to diagnostic precision. In addition, Cook provides a variety of biopsy instruments, such as endoscopic forceps and transrectal instruments, to meet different clinical requirements. This diversity makes Cook a good supplier for hospitals. Further, the company's focus on clinical validation is reflected in the high rates of physician satisfaction during EchoTip ClearCore pre-launch assessment, with 94% indicating they would repeat use of the device. This clinical support increases confidence among procurement committees and gives Cook Medical a market advantage in the biopsy market through sophisticated device accuracy, diversity of portfolio, and established reliability.

SWOT Analysis of the INRAD, Inc Company

Strength: Innovation & Unique "No-Throw" Biopsy Technology - INRAD, Inc. excels due to its innovative approach, especially with the "No-Throw" biopsy technology in the PreciseCore device. In contrast to conventional core-needle devices that push the stylet forward and potentially compromise surrounding tissues, the PreciseCore takes specimens without such forward movement. This makes the design more secure, minimizes the possibility of overshoot trauma, and maximizes precision for soft tissue biopsies. The PreciseCore is easy to handle, one-handed, ultrasound-compatible, and has distinct depth markings for precise targeting. Also, INRAD provides a variety of biopsy needle types with versatility and customization, enabling clinicians to choose tools that best fit particular anatomical and procedural requirements. Such strengths give INRAD a competitive advantage in providing precise and safer biopsy solutions.

CONMED Corporation Recent Development in Biopsy Devices Market

CONMED Corporation has completed its acquisition of In2Bones Global Inc., a privately-held firm. The deal is being funded through a combination of funds, including net proceeds from the Company's 2.25% convertible notes issued in June 2022, borrowings under the Company's amended and restated credit facility, and cash on hand.

Argon Medical Devices, Inc. Recent Development in Biopsy Devices Market

May 2023, Argon Medical Devices introduced the SuperCore Advantage™ Semi-Automatic Biopsy Instrument, expanding its U.S. soft tissue biopsy product line. The disposable device retrieves a greater volume of tissue samples*, potentially enhancing diagnostic accuracy. It is offered in multiple lengths and gauge sizes to enable physicians to select the optimal fit for their clinical requirement.

Stryker Corporation Sustainability Goal

Decrease Scope 1 and 2 greenhouse gas emissions for Stryker's buildings by 20% by 2024 and achieve carbon neutrality by 2030. Stryker Corporation road to carbon neutrality relies on shifting from fossil fuel-derived to renewable electricity, and we're working towards being powered by 100 percent renewable electricity worldwide by 2027. This electricity will be sourced from a mix of wind, solar, hydroelectric and others.

B. Braun Melsungen AG Sustainability Goal

B. Braun Melsungen AG targets Scope 1 and 2 greenhouse gas emissions to decrease by 50% by 2030 from a 2021 base. Energy efficiency is a key focus for the company, with 25% of annual energy savings following a new Hanoi plant, which saves around 1,700 metric tons of CO₂ equivalents yearly. The expansion of plant W in Melsungen allows greenhouse gas-neutral production of dialysis machines and infusion pumps by utilizing photovoltaics, energy recovery, heat pumps, an underground ice storage system, and renewable electricity.

Global Biopsy Devices Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Global Biopsy Devices Industry

Company Analysis

Overview

• Company History and Mission
• Business Model and Operations
• Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

• Cardinal Health, Inc
• Hologic, Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Medtronic plc.
• Olympus Corporation
• CONMED Corporation
• Argon Medical Devices, Inc.
• Cook Medical (Cook Group)
• INRAD, Inc.
• FUJIFILM Holdings Corporation
• Stryker Corporation
• Merit Medical Systems, Inc.
• B. Braun Melsungen AG